Several major global pharmaceutical enterprises compete for having the most advanced and lucrative oncology pipelines, anchored by heavy investments in antibody-drug conjugates (ADCs), bispecific antibodies, and immuno-oncology therapies. Industry leaders such as AstraZeneca, Merck, Roche, Novartis, and Pfizer consistently lead clinical trial output metrics, driven by extensive research budgets and strategic acquisitions of smaller biotech innovators.